As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of BioNexus Gene Lab Corp. The largest reported stake is Fidelion Diagnostics Pte. Ltd.'s, at 13.4%. 2 filings are on record since August 14, 2026 (Schedule 13G, October 22, 2026).
Sell to companies like BioNexus Gene Lab Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
BioNexus Gene Lab Corp has 2 Schedule 13D or 13G filings on record since 2026-08-14. 2 holders' latest filing reports 5% or more of common stock, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fidelion Diagnostics Pte. Ltd. | 13.4% | 392,329 | SCHEDULE 13G, 2026-10-22 | 2025-11-28 |
| 11.5% | 338,709 | SCHEDULE 13D, 2026-08-14 | 2026-08-13 |
Holding shares or following this stake? See who's behind BioNexus Gene Lab Corp and the warning signs.
Free to see. No signup.
Watch BioNexus Gene Lab Corp
Get an email when BioNexus Gene Lab Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BioNexus Gene Lab Corp?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on BioNexus Gene Lab Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioNexus Gene Lab Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fidelion Diagnostics Pte. Ltd. | 392,329 | 0 | 392,329 | 0 | SCHEDULE 13G, 2026-10-22 |
| Molecule Bio LLC | 0 | 392,329 | 0 | 392,329 | SCHEDULE 13G, 2026-10-22 |
| Xiao Ling | 0 | 392,329 | 0 | 392,329 | SCHEDULE 13G, 2026-10-22 |
| Rainy Morning Technology (Hong Kong) Limited | 0 | 392,329 | 0 | 392,329 | SCHEDULE 13G, 2026-10-22 |
| Tan Lee Su-Leng | 338,709 | 0 | 338,709 | 0 | SCHEDULE 13D, 2026-08-14 |
The latest filing identifies BioNexus Gene Lab Corp by CUSIP 090628306 and gives its principal executive office as UNIT A-28-7, TOWER A, MENARA UOA BANGSAR, NO. 5 JLN BANGSAR UTAMA 1, Kuala Lumpur (SCHEDULE 13G, 2026-10-22).
Source of funds (Item 3)
On August 13, 2026, the Issuer granted and issued effective as of that date to the Reporting Person a fully vested Other Stock-Based Award covering 338,709 shares of Common Stock under Section 5 of the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan (the 'Plan'). The award was separately approved on a basis for completed services and for no cash consideration. Accordingly, no personal funds were used to acquire the shares. The source-of-funds code reported on the cover page is 'OO' (Other).Tan Lee Su-Leng, SCHEDULE 13D, 2026-08-14
Purpose of Transaction (Item 4)
Tan Lee Su-Leng
The Reporting Person acquired the shares as compensation for completed services to the Issuer and in connection with the Reporting Person's service as Chief Executive Officer and President and as a director. The shares were not acquired with borrowed funds or for the purpose of acquiring control of the Issuer. By reason of the Reporting Person's executive and Board positions, the Reporting Person participates in the management, business, policies and strategic direction of the Issuer and may from time to time consider, discuss or support actions concerning the Issuer's business, operations, governance, capital structure, securities, financing, acquisitions or dispositions, Board composition, executive leadership and other matters that may fall within one or more of the categories described in Item 4(a) through (j) of Schedule 13D. Any such action would remain subject to the Reporting Person's fiduciary duties, applicable law, the Issuer's governing documents and required approvals. Except as described in this statement and in the Reporting Person's ordinary exercise of responsibilities as an executive officer and director, the Reporting Person has no present plan or proposal that relates to or would result in any action specified in Item 4(a) through (j) of Schedule 13D. The Reporting Person may review the investment on a continuing basis and may change this intention in light of future developments.Item 4 of the SCHEDULE 13D filed 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-08-14 | Tan Lee Su-Leng | 11.5% | SCHEDULE 13D |
| 2026-10-22 | Fidelion Diagnostics Pte. Ltd. | 13.4% | SCHEDULE 13G |
Questions about who owns BioNexus Gene Lab Corp
Who owns BioNexus Gene Lab Corp?
On this page, 2 holders' latest ownership filings report 5% or more of BioNexus Gene Lab Corp: Fidelion Diagnostics Pte. Ltd. (13.4%, Schedule 13G, filed 2026-10-22) and Tan Lee Su-Leng (11.5%, Schedule 13D, filed 2026-08-14).
Who are the largest shareholders of BioNexus Gene Lab Corp?
By the share each holder's latest filing reports, the largest holders of BioNexus Gene Lab Corp on this page are Fidelion Diagnostics Pte. Ltd. (13.4%) and Tan Lee Su-Leng (11.5%).
When did Fidelion Diagnostics Pte. Ltd. buy into BioNexus Gene Lab Corp?
The filings give report dates, not purchase dates. The earliest filing from Fidelion Diagnostics Pte. Ltd. on this page is the Schedule 13G, filed 2026-10-22, reporting 13.4%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for BioNexus Gene Lab Corp. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.